Fasinumab

From WikiProjectMed
Jump to navigation Jump to search
Fasinumab
Monoclonal antibody
Type?
SourceHuman
TargetHNGF
Clinical data
ATC code
  • none
Identifiers
CAS Number
ChemSpider
  • none
UNII
KEGG
Chemical and physical data
FormulaC6406H9896N1700O2026S46
Molar mass144618.27 g·mol−1

Fasinumab is a human monoclonal antibody designed for the treatment of acute sciatic pain.[1][2]

This drug was developed in collaboration by Teva Pharmaceutical Industries and Regeneron Pharmaceuticals.

It is currently at Phase III trials (NCT03245008, NCT02683239, and NCT03161093).[3]

See also

References

  1. ^ "Fasinumab" (PDF). Statement On A Nonproprietary Name Adopted By The USAN Council. American Medical Association.
  2. ^ Tiseo PJ, Ren H, Mellis S (2014). "Fasinumab (REGN475), an antinerve growth factor monoclonal antibody, for the treatment of acute sciatic pain: results of a proof-of-concept study". Journal of Pain Research. 7: 523–30. doi:10.2147/JPR.S65974. PMC 4155988. PMID 25210473.
  3. ^ Oo, Win Min; Hunter, David J. (2021-11-01). "Nerve Growth Factor (NGF) Inhibitors and Related Agents for Chronic Musculoskeletal Pain: A Comprehensive Review". BioDrugs. 35 (6): 611–641. doi:10.1007/s40259-021-00504-8. ISSN 1179-190X.